Jefferies Starts Allergen (AGN) at Hold

Go back to Jefferies Starts Allergen (AGN) at Hold

Edward Jones Downgrades Allergen (AGN) to Sell

April 23, 2014 2:06 PM EDT

Edward Jones downgraded Allergen (NYSE: AGN) from Hold to Sell.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $163.65 yesterday.

... More

JPMorgan Upgrades Allergen (AGN) to Overweight

April 23, 2014 6:35 AM EDT

JPMorgan upgraded Allergen (NYSE: AGN) from Neutral to Overweight with a price target of $190.00 (from $130.00).

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $163.65 yesterday.

... More

Argus Downgrades Allergen (AGN) to Hold

April 22, 2014 2:56 PM EDT

Argus downgraded Allergen (NYSE: AGN) from Buy to Hold with a price target of $130.00 (unchanged).

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $142.00 yesterday.

... More

Allergan (AGN) Plans to Carefully Review Valeant (VRX) Offer

April 22, 2014 11:06 AM EDT

Allergan, Inc. (NYSE: AGN) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant... More

Pharma M&A May be Entering Megadeals Phase, Says Goldman Sachs Analyst (AGN) (VRX) (PFE) (AZN) (ACT) (FRX)

April 22, 2014 8:44 AM EDT

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced Tuesday that it has submitted a merger proposal to the Board of Directors of Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of... More

Valeant (VRX) Enters Cash, Stock Bid for Allergan (AGN)

April 22, 2014 7:34 AM EDT

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it has submitted a merger proposal to the Board of Directors of Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. Shareholders will be able to elect a mix of cash and shares, subject to proration. The proposal represents a substantial premium based on Allergan's unaffected price of $116.63 on April 10, 2014, the day before Pershing Square Capital Management L.P.... More